Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.63 |
| ▸ | CNR1 | P21554 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990707 | 0.83 | CNR2 (0.49) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5601173 | 0.78 | CNR2 (0.45) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3993498 | 0.78 | CNR2 (1.00) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3988980 | 0.78 | CNR1 (0.39) | CNR2CNR1LMNAHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3990544 | 0.78 | CNR2 (0.98) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3987318 | 0.77 | CNR2 (0.71) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3996521 | 0.76 | CNR2 (0.70) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12697384 | 0.76 | PLAUR (0.53) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4791767 | 0.76 | CNR1 (0.47) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3987827 | 0.75 | CNR1 (0.64) | CNR2CNR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1753764-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121140-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219229-A1 | Pyrrolopyridine Derivatives | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885CYP3A4 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.